Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RaySearch Laboratories and Ion Beam Applications, or IBA, have announced that the new dosimetry solution Compass has received 510(k) clearance by the FDA and that it has been launched on the worldwide market through IBA's business unit IBA Dosimetry.
Subscribe to our email newsletter
According to RaySearch, Compass is a state-of-the-art solution for quality assurance in radiotherapy used to measure and reconstruct the 3D radiation dose that was actually delivered to the patient every day during the course of treatment.
Pierre Mottet, CEO of IBA, said: “The Compass FDA clearance and market launch is the culmination of two years of joint effort with RaySearch Laboratories to design this novel dosimetry solution that will allow radiotherapy departments to cope with the highest treatment accuracy and reliability standards. We are excited to be the first company in the world to propose such an online dosimetry solution that will increase treatment efficiency and save lives.”